Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lucarelli, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lucarelli, C.
American Journal of Health-System Pharmacy, Vol 60, Issue suppl_1, S4-S11
Copyright © 2003 by American Society of Health-System Pharmacists

Articles

Formulary management strategies for type 3 serotonin receptor antagonists

CD Lucarelli


The efficacy of type 3 serotonin (5-hydroxytryptamin) (5-HT3) receptor antagonists in preventing nausea and vomiting associated with cancer chemotherapy, radiation therapy, and surgery and the role of practice guidelines for the use of these agents in controlling antiemetic drug costs without compromising patient care are described. Nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery can have a negative impact on quality of life and patient outcomes. The 5-HT3 receptor antagonists are effective for preventing nausea and vomiting from these causes. Oral 5-HT3 receptor antagonist therapy is as effective as intravenous therapy, while usually costing less. Various factors associated wtih the patient and the chemotherapy, radiation therapy, or surgery that increase the risk for nausea and vomiting have been identified. Practice guidelines have been developed in which 5-HT3 receptor antagonist therapy is reserved for patients at high risk for nausea and vomiting based on these various factors. The use of such practice guidelines at Memorial Sloan-Kettering Cancer Center limited antiemetic drug expenditures despite an increase in the number of patients receiving cancer treatment without compromising emetic control or quality of life. The use of special order forms improved compliance with the practice guidelines.
 



This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
ASHP Guidelines on Medication Cost Management Strategies for Hospitals and Health Systems
Am. J. Health Syst. Pharm., July 15, 2008; 65(14): 1368 - 1384.
[Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
M. B. Toma and P. J. Medina
Update on Targeted Therapy--Focus on Monoclonal Antibodies
Journal of Pharmacy Practice, February 1, 2008; 21(1): 4 - 16.
[Abstract] [PDF]

Home page
 CirculationHome page
A. Kulier, J. Levin, R. Moser, G. Rumpold-Seitlinger, I. C. Tudor, S. A. Snyder-Ramos, P. Moehnle, D. T. Mangano, and for the Investigators of the Multicenter Study of
Impact of Preoperative Anemia on Outcome in Patients Undergoing Coronary Artery Bypass Graft Surgery
Circulation, July 31, 2007; 116(5): 471 - 479.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
H. Tamer and N. Shehab
Using preprinted medication order forms to improve the safety of investigational drug use.
Am. J. Health Syst. Pharm., June 1, 2006; 63(11): 1022 - 1028.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Society of Health-System Pharmacists.